1
|
Behera B, Nayak AK, Dash S, Sethy M, Ayyanar P. Acantholytic PRIDE syndrome. J Cutan Pathol 2024. [PMID: 38987224 DOI: 10.1111/cup.14684] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/08/2024] [Revised: 06/23/2024] [Accepted: 07/01/2024] [Indexed: 07/12/2024]
Affiliation(s)
- Biswanath Behera
- Department of Dermatology and Venereology, AIIMS, Bhubaneswar, India
| | | | - Siddhartha Dash
- Department of Dermatology and Venereology, AIIMS, Bhubaneswar, India
| | | | | |
Collapse
|
2
|
Song CH, Jeong M, In H, Kim JH, Lin CW, Han KH. Trends in the Development of Antibody-Drug Conjugates for Cancer Therapy. Antibodies (Basel) 2023; 12:72. [PMID: 37987250 PMCID: PMC10660735 DOI: 10.3390/antib12040072] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/14/2023] [Revised: 10/28/2023] [Accepted: 10/31/2023] [Indexed: 11/22/2023] Open
Abstract
In cancer treatment, the first-generation, cytotoxic drugs, though effective against cancer cells, also harmed healthy ones. The second-generation targeted cancer cells precisely to inhibit their growth. Enter the third-generation, consisting of immuno-oncology drugs, designed to combat drug resistance and bolster the immune system's defenses. These advanced therapies operate by obstructing the uncontrolled growth and spread of cancer cells through the body, ultimately eliminating them effectively. Within the arsenal of cancer treatment, monoclonal antibodies offer several advantages, including inducing cancer cell apoptosis, precise targeting, prolonged presence in the body, and minimal side effects. A recent development in cancer therapy is Antibody-Drug Conjugates (ADCs), initially developed in the mid-20th century. The second generation of ADCs addressed this issue through innovative antibody modification techniques, such as DAR regulation, amino acid substitutions, incorporation of non-natural amino acids, and enzymatic drug attachment. Currently, a third generation of ADCs is in development. This study presents an overview of 12 available ADCs, reviews 71 recent research papers, and analyzes 128 clinical trial reports. The overarching objective is to gain insights into the prevailing trends in ADC research and development, with a particular focus on emerging frontiers like potential targets, linkers, and drug payloads within the realm of cancer treatment.
Collapse
Affiliation(s)
- Chi Hun Song
- Department of Biological Sciences and Biotechnology, Hannam University, Daejeon 34054, Republic of Korea; (C.H.S.); (M.J.); (H.I.); (J.H.K.)
| | - Minchan Jeong
- Department of Biological Sciences and Biotechnology, Hannam University, Daejeon 34054, Republic of Korea; (C.H.S.); (M.J.); (H.I.); (J.H.K.)
| | - Hyukmin In
- Department of Biological Sciences and Biotechnology, Hannam University, Daejeon 34054, Republic of Korea; (C.H.S.); (M.J.); (H.I.); (J.H.K.)
| | - Ji Hoe Kim
- Department of Biological Sciences and Biotechnology, Hannam University, Daejeon 34054, Republic of Korea; (C.H.S.); (M.J.); (H.I.); (J.H.K.)
| | - Chih-Wei Lin
- Institute of Biochemistry and Molecular Biology, China Medical University, Taichung 406, Taiwan;
| | - Kyung Ho Han
- Department of Biological Sciences and Biotechnology, Hannam University, Daejeon 34054, Republic of Korea; (C.H.S.); (M.J.); (H.I.); (J.H.K.)
| |
Collapse
|
3
|
Nowaczyk J, Fret K, Kaminska-Winciorek G, Rudnicka L, Czuwara J. EGFR inhibitor-induced folliculitis decalvans: a case series and management guidelines. Anticancer Drugs 2023; 34:942-948. [PMID: 36708507 PMCID: PMC10414157 DOI: 10.1097/cad.0000000000001494] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/20/2022] [Revised: 11/21/2022] [Indexed: 01/29/2023]
Abstract
Epidermal growth factor receptor (EGFR) is one of therapeutic targets in oncology for solid tumors originating from epithelial tissue, such as non-small-cell lung carcinoma (NSCLC) and breast cancer. EGFR inhibitors used in cancer treatment may cause a broad spectrum of dose-dependent cutaneous adverse events, including acneiform papulopustular rash, nail and hair disturbances, xerosis, and mucositis. The pathogenesis of the EGFR inhibitor-induced adverse reactions originates from disturbances in keratinocyte differentiation, cytokine secretion, and neutrophil chemotaxis. One of the rare, yet distressing adverse events may be folliculitis decalvans, a progressive neutrophil-driven scarring alopecia with hair tufts formation resembling doll's hair. Early diagnosis and introduction of treatment are crucial for disease prognosis since a long course of the disease leads to decreased quality of life. Here, we review the literature cases of EGFR inhibitor-induced folliculitis decalvans and provide guidance on management and prevention of this condition in oncologic patients. Furthermore, we report the first afatinib-associated folliculitis decalvans in three female patients with NSCLC.
Collapse
Affiliation(s)
- Joanna Nowaczyk
- Department of Dermatology, Medical University of Warsaw, Warsaw
| | - Kamil Fret
- Department of Dermatology, Medical University of Warsaw, Warsaw
| | - Grazyna Kaminska-Winciorek
- Department of Bone Marrow Transplantation and Onco-Haematology, Maria Sklodowska-Curie National Research Institute of Oncology (MSCNRIO), Gliwice Branch, Poland
| | - Lidia Rudnicka
- Department of Dermatology, Medical University of Warsaw, Warsaw
| | - Joanna Czuwara
- Department of Dermatology, Medical University of Warsaw, Warsaw
| |
Collapse
|
4
|
Alhanshali L, Buontempo M, Shapiro J, Lo Sicco K. Medication-induced hair loss: An update. J Am Acad Dermatol 2023; 89:S20-S28. [PMID: 37591561 DOI: 10.1016/j.jaad.2023.04.022] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/31/2022] [Revised: 03/24/2023] [Accepted: 04/06/2023] [Indexed: 08/19/2023]
Abstract
This article discusses drug-induced hair loss, which can occur with many drugs including cytotoxic agents, biologics, and immunomodulating agents, among others. It outlines the diagnosis and management of drug-induced alopecia, with a focus on recently implicated drugs.
Collapse
Affiliation(s)
- Lina Alhanshali
- Department of Dermatology, SUNY Downstate College of Medicine, Brooklyn, New York
| | - Michael Buontempo
- Department of Dermatology, Hackensack Meridian School of Medicine, Nutley, New Jersey
| | - Jerry Shapiro
- The Ronald O. Perelman Department of Dermatology, New York University Grossman School of Medicine, New York, New York
| | - Kristen Lo Sicco
- The Ronald O. Perelman Department of Dermatology, New York University Grossman School of Medicine, New York, New York.
| |
Collapse
|
5
|
Jeria S, Thool AR, Daigavane S, Ganjre S. Ocular Adverse Effects of Gefitinib: A Case Report. Cureus 2022; 14:e29600. [PMID: 36320985 PMCID: PMC9599912 DOI: 10.7759/cureus.29600] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/07/2022] [Accepted: 09/26/2022] [Indexed: 11/25/2022] Open
Abstract
Gefitinib is a selective epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor. It is used for treating locally advanced or metastatic non-small cell lung carcinoma and is well tolerated systemically. However, sight-threatening ocular adverse effects, like corneal ulcer and perforation, can occur due to the expression of EGFR on limbal and conjunctival epithelia. In this report, we describe a case of a 36-year-old female who presented with loss of eyebrow hair and eyelashes of both eyes and blurring of vision in the right eye. On ocular examination, the patient had anterior blepharitis, madarosis, punctuate epithelial erosions and reduced corneal sensation in both eyes, and corneal thinning in the right eye. On specular microscopy, there was decreased central corneal thickness in both eyes. Treatment with topical antibiotics and lubricating drops led to the resolution of blepharitis and punctate epithelial erosions. This case report aims to create awareness among ophthalmologists and oncologists about the early detection of gefitinib-related ocular adverse effects and timely intervention in patients.
Collapse
|
6
|
Kumar Chaudhary R, Bhandari R, Doshi B, Karoli SS, Spoorthi Marripalli S, Ganachari MS. Gefitinib induced Pemphigus Vulgaris with PRIDE complex. J Oncol Pharm Pract 2022; 28:1465-1473. [PMID: 35102778 DOI: 10.1177/10781552221076755] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
Abstract
Introduction: Pemphigus Vulgaris is a rare, noncommunicable, non-hereditary fatal autoimmune dermatological manifestation in which a painful blister initiates from the oral cavity. PRIDE complex stands for Papulopustules or paronychia, regulatory abnormality of hair and nails, itching, and dryness due to inhibition of EGFR. Both of these mucocutaneous manifestations are rare and are often caused by drugs. Case report: Our case reports 53-year-old patient presented with multiple crusted plaques, multiple hyperpigmented macules to patches, Solitary fluid-filled lesions on several parts of the body, and numerous erosions positive over buccal mucosa on initial follow up which was diagnosed as Pemphigus Vulgaris with PRIDE complex induced by Gefitinib. Management and outcome: The patient was treated with almost all possible treatment options, i.e., both steroids plus adjuvant therapy for pemphigus and antihistaminic, antibiotics, moisturizer, and lotions for PRIDE complex. The patient was initially admitted for infusion of the first dose of rituximab and later for management of flare-up condition and infusion of the second dose of rituximab infusion. Discussion: The complexity of the management of Pemphigus Vulgaris and PRIDE complex demands adequate monitoring of the patient's anti-cancerous therapy by clinical pharmacists, which can impact the clinical outcomes by providing pharmaceutical care and minimize the economic burden.
Collapse
Affiliation(s)
- Raushan Kumar Chaudhary
- Department of Pharmacy Practice, 58890KLE College of Pharmacy, A Constituent Unit of KLE Academy of Higher Education and Research (KAHER), Belagavi, Karnataka, India
| | - Ramesh Bhandari
- Department of Pharmacy Practice, 58890KLE College of Pharmacy, A Constituent Unit of KLE Academy of Higher Education and Research (KAHER), Belagavi, Karnataka, India
| | - Bhavana Doshi
- Department of Dermatology, 29178J N Medical College, A Constituent Unit of KLE Academy of Higher Education and Research (KAHER), Belagavi, Karnataka, India
| | - Satish S Karoli
- Department of Pharmacy Practice, 58890KLE College of Pharmacy, A Constituent Unit of KLE Academy of Higher Education and Research (KAHER), Belagavi, Karnataka, India
| | - Sowmya Spoorthi Marripalli
- Department of Pharmacy Practice, 58890KLE College of Pharmacy, A Constituent Unit of KLE Academy of Higher Education and Research (KAHER), Belagavi, Karnataka, India
| | - M S Ganachari
- Department of Pharmacy Practice, 58890KLE College of Pharmacy, A Constituent Unit of KLE Academy of Higher Education and Research (KAHER), Belagavi, Karnataka, India
| |
Collapse
|
7
|
Abstract
Abstract
Current therapies for Head and Neck cancer treatment are extremely advanced. Though, they cause oral complications which have deleterious effects on basic life functions, affect oral and overall health, may lead to significant morbidity and treatment discontinuation and have an impact on survivorship and quality of life. As new therapies are introduced, a new spectrum of oral complications is rising, compromising the mucosal integrity and the salivary function, that may not be recognized, reported and treated properly. Oral complications, often permanent and extremely painful, may include mucositis, xerostomia, dysgeusia, infections, trismus and fibrosis, risk of dental disease and necrosis of the jaw, neurosensory disorders and when targeted therapies and immunotherapy are involved, aphthoid and lichenoid lesions can also be reported. Increased awareness is required for the prevention and management of these complications, which can be best provided by a multidisciplinary team.
Collapse
|
8
|
Yorulmaz A, Yalcin B. Panitumumab-Induced Paronychia: A Case Report and a Brief Review of the Literature. Skin Appendage Disord 2021; 7:123-126. [PMID: 33796558 DOI: 10.1159/000512036] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/21/2020] [Accepted: 10/04/2020] [Indexed: 11/19/2022] Open
Abstract
Panitumumab is a recombinant, fully humanized IgG2 monoclonal antibody targeting the epidermal growth factor receptor (EGFR). Panitumumab is indicated for patients with metastatic colorectal cancer with progressive refractory disease. Targeted therapies are well known to be well tolerated; however, they may induce toxicities that are distinct from those of classical chemotherapeutic agents. For instance, EGFR inhibitors (EGFRIs) are associated with some specific dermatological adverse effects, one of which is nail toxicity. Since panitumumab is fully humanized, unlike most of the other EGFRIs, it has been reported to have reduced incidence of adverse reactions. Nail-related adverse effects are frequently observed with EGFRIs. A literature search has yielded a list of reviews describing panitumumab-induced nail toxicity. However, as far as we know, there is no case report detailing this adverse effect of panitumumab. Here, we present a case of panitumumab-induced paronychia in a 60-year-old woman with metastatic colon cancer. With this case report, we would like to review the literature and discuss the possible underlying mechanisms of this condition.
Collapse
Affiliation(s)
- Ahu Yorulmaz
- Department of Dermatology, Ankara Bilkent City Hospital, Ankara, Turkey
| | - Basak Yalcin
- Department of Dermatology, Ankara Bilkent City Hospital, Ankara, Turkey
| |
Collapse
|
9
|
de Almeida HL, Sartori DS, de Almeida AL, Ruas CP, Zerwes G. Scanning Electron Microscopy of Subclinical Gefitinib-Induced Hair Changes. Int J Trichology 2020; 12:129-131. [PMID: 33223740 PMCID: PMC7659746 DOI: 10.4103/ijt.ijt_69_20] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/03/2020] [Revised: 07/17/2020] [Accepted: 07/21/2020] [Indexed: 12/13/2022] Open
Abstract
Oral inhibitors of epidermal growth factor receptor may have a wide range of cutaneous manifestations. Hair manifestations are observed in 10%-20% of the patients. At the ultrastructural level erlotinib-induced hair changes were already described as acquired pili torti et canaliculi. We examined a 78-year-old female patient, with lung carcinoma, taking gefitinib for 15 months. The treatment has no side effects with good tolerance and tumor response. Although the patient had not observed any change on the hairs under the therapy, some specimens were obtained to be examined in natura with scanning electron microscopy. Under low magnification incipient grooving was observed on the hair surface, tortions or angulations of the hair shaft were not found. With higher magnifications the surface grooving was even more evident. Our findings show that gefitinib may cause subclinical hair changes, similar to those described at the ultrastructural level with erlotinib.
Collapse
Affiliation(s)
- Hiram Larangeira de Almeida
- Department of Dermatology, Catholic and Federal University of Pelotas, Rio Grande, Brazil.,Post-Graduation Program in Health Sciences, Catholic University of Pelotas, Rio Grande, Brazil
| | - Debora Sarzi Sartori
- Post-Graduation Program in Health Sciences, Catholic University of Pelotas, Rio Grande, Brazil
| | | | - Caroline Pires Ruas
- Electron Microscopy Center, Federal University of Rio Grande, Rio Grande, Brazil
| | | |
Collapse
|
10
|
Çelik U, Aydemir EH, Engin B, Oba MÇ, Yılmaz M, Meşe ŞG. Dermatological side effects of immunotherapy drugs and targeted cancer therapies: Importance of dermatology and oncology collaboration. J Oncol Pharm Pract 2020; 27:1853-1860. [PMID: 33131448 DOI: 10.1177/1078155220970621] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/25/2023]
Abstract
INTRODUCTION Novel anti-cancer drugs such as targeted cancer therapies and immune check-point inhibitors (ICIs) have adverse events, especially concerning the skin. The aim of this study is to report an overview of the commonly consulted dermatological side effects of ICIs and targeted cancer therapies in clinical practice, along with their management. METHODS In this single-center study, we evaluated consecutive oncological patients who were referred from the oncology outpatient clinic to the dermatology outpatient clinic due to skin side effects of ICIs and targeted therapies. All patients were examined and treated at the same day of referral by experienced dermatologists. Patient characteristics, clinical findings, diagnostic workups and treatments were retrieved from outpatient records. RESULTS Sixty three patients were enrolled. Most common diagnoses were lung carcinoma, melanoma and colon carcinoma. Fifty patients (79%) were using targeted therapies while 13 (21%) were using ICIs. Xerosis was the most common side effect (44%), followed by acneiform rash, paronychia, eczema and pruritus. Majority of the side effects were grade 2 and 3. Psoriasis was a common side effect of ICIs. One patient had a newly developed dysplastic nevus on vemurafenib treatment. Oncological treatment was not withheld in any of the patients. CONCLUSIONS This study revealed the most commonly consulted skin side effects of novel anti-cancer drugs and their management in daily practice. We underlie the importance of collaborative work of oncology and dermatology professionals as early management of cutaneous side effects of targeted therapies and ICIs improves patient outcomes.
Collapse
Affiliation(s)
- Uğur Çelik
- Department of Dermatology and Venerology, Cerrahpasa Medical Faculty, Istanbul University-Cerahpasa, Istanbul, Turkey
| | - Ertuğrul H Aydemir
- Department of Dermatology and Venerology, Cerrahpasa Medical Faculty, Istanbul University-Cerahpasa, Istanbul, Turkey
| | - Burhan Engin
- Department of Dermatology and Venerology, Cerrahpasa Medical Faculty, Istanbul University-Cerahpasa, Istanbul, Turkey
| | - Muazzez Ç Oba
- Department of Dermatology and Venerology, Cerrahpasa Medical Faculty, Istanbul University-Cerahpasa, Istanbul, Turkey
| | - Mesut Yılmaz
- Department of Medical Oncology, Cerrahpasa Medical Faculty, Istanbul University-Cerahpasa, Istanbul, Turkey
| | - Şermin Güven Meşe
- Department of Medical Oncology, Cerrahpasa Medical Faculty, Istanbul University-Cerahpasa, Istanbul, Turkey
| |
Collapse
|
11
|
Bhanja DB, Sil A, Punithakumar EJ, Panigrahi A, Das A, Biswas SK. PRIDE syndrome. Postgrad Med J 2020; 97:489-490. [PMID: 32601257 DOI: 10.1136/postgradmedj-2020-137939] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/19/2020] [Revised: 06/01/2020] [Accepted: 06/06/2020] [Indexed: 11/03/2022]
Affiliation(s)
- Dibyendu Bikash Bhanja
- Dermatology, Venereology, and Leprosy, RG Kar Medical College and Hospital, Kolkata, India
| | - Abheek Sil
- Dermatology, Venereology, and Leprosy, RG Kar Medical College, Kolkata, India
| | - Esther J Punithakumar
- Dermatology, Venereology, and Leprosy, RG Kar Medical College and Hospital, Kolkata, India
| | - Avik Panigrahi
- Dermatology, Venereology, and Leprosy, RG Kar Medical College and Hospital, Kolkata, India
| | - Avijit Das
- Dermatology, Venereology, and Leprosy, RG Kar Medical College and Hospital, Kolkata, India
| | | |
Collapse
|
12
|
de Almeida HL, Sartori DS, Deves RP, Cruz OM. Scanning Electron Microscopy of Erlotinib-induced Hair Changes: Pili Torti et Canaliculi. Int J Trichology 2020; 11:238-240. [PMID: 32030058 PMCID: PMC6984046 DOI: 10.4103/ijt.ijt_98_19] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/10/2023] Open
Abstract
The cutaneous toxicity of the epidermal growth factor receptor inhibitors, such as erlotinib, is associated with a wide range of manifestations, such as papulopustular eruptions, xerosis, paronychia, and changes in the growth pattern of hair and nails. Hair manifestations are seen in 10%–20% of the patients. A female patient taking erlotinib for lung cancer for 8 months noticed that her scalp hair became rough on palpation and that her eyelashes were elongated. Some scalp hairs were cut and proximal and distal portions were examined in natura with scanning electron microscopy. Torsions and important grooving were seen in the proximal portions, but not in distal hair portions. Erlotinib-induced hair changes are pili torti et canaliculi.
Collapse
Affiliation(s)
- Hiram Larangeira de Almeida
- Post-Graduation Program in Health, Catholic University of Pelotas, Brazil.,Dermatology League, Federal University of Pelotas, Brazil
| | - Débora Sarzi Sartori
- Post-Graduation Program in Health, Catholic University of Pelotas, Brazil.,Dermatology League, Federal University of Pelotas, Brazil
| | | | | |
Collapse
|